Plain-English translation of NCT07746947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The PROMISE Registry is studying how doctors are currently treating a specific type of acute stroke caused by medium vessel occlusions—blockages in medium-sized brain blood vessels. This observational study will follow patients who receive different treatment approaches, including mechanical clot removal (a catheter-based procedure), clot-busting medications given through an IV, or medical management alone. By tracking real-world treatment patterns and outcomes, researchers hope to better understand what works best for this type of stroke.
Recent clinical trials have raised new questions about the best way to treat medium vessel strokes, and doctors across the country may have different opinions about which approach is best. This study exists to understand current medical practice and help guide future treatment decisions based on what actually happens to patients in everyday hospital settings.
You likely qualify if…
You likely don't qualify if…
If you join this registry, you will be followed as part of a group receiving either a catheter-based procedure to remove the clot, clot-busting medication through an IV, or medical management, depending on what your doctors decide is best for you. Researchers will collect information about your treatment, imaging results, and how you recover over time. You will need to give informed consent within the first 72 hours after being included in the study.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States
Sponsor
Indiana University
Collaborators
phenox Inc.
Enrollment target
~652 participants
Started
July 2026
Primary completion
July 2029
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kaustubh Limaye, MD, FAHA
Indiana University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.